Salvador Augustin
Overview
Explore the profile of Salvador Augustin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
1937
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sanchez-Aldehuelo R, Villanueva C, Genesca J, Garcia-Pagan J, Castillo E, Calleja J, et al.
JHEP Rep
. 2025 Jan;
7(2):101231.
PMID: 39850960
Background & Aims: Systemic inflammation is a driver of decompensation in cirrhosis with unclear relevance in the compensated stage. We evaluated inflammation and bacterial translocation markers in compensated cirrhosis and...
2.
Pericas J, Anstee Q, Augustin S, Bataller R, Berzigotti A, Ciudin A, et al.
Nat Rev Gastroenterol Hepatol
. 2024 Aug;
21(11):824.
PMID: 39103628
No abstract available.
3.
Pericas J, Anstee Q, Augustin S, Bataller R, Berzigotti A, Ciudin A, et al.
Nat Rev Gastroenterol Hepatol
. 2024 Jul;
21(11):809-823.
PMID: 39020089
Although metabolic dysfunction-associated steatohepatitis (MASH) is rapidly becoming a leading cause of cirrhosis worldwide, therapeutic options are limited and the number of clinical trials in MASH-related compensated cirrhosis is low...
4.
Amoroso M, Augustin S, Moosmang S, Gashaw I
J Mol Med (Berl)
. 2024 May;
102(7):841-858.
PMID: 38753041
Liver cirrhosis due to nonalcoholic steatohepatitis (NASH) is a life-threatening condition with increasing incidence world-wide. Although its symptoms are unspecific, it can lead to decompensation events such as ascites, hepatic...
5.
Rivera-Esteban J, Jimenez-Masip A, Munoz-Martinez S, Augustin S, Guerrero R, Gabriel-Medina P, et al.
J Clin Med
. 2023 Dec;
12(23).
PMID: 38068330
Background And Aims: The prevalence of chronic non-communicable diseases, particularly metabolic syndrome (MetS), has increased among the prison population. Nevertheless, we have limited data on metabolic dysfunction-associated steatotic liver disease...
6.
Gabriel-Medina P, Ferrer-Costa R, Ciudin A, Augustin S, Rivera-Esteban J, Pericas J, et al.
Intern Emerg Med
. 2023 Nov;
19(3):745-756.
PMID: 37952070
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease, and liver fibrosis is the strongest predictor of morbimortality. We aimed to assess the performance of a...
7.
Pons M, Rivera-Esteban J, Ma M, Davyduke T, Delamarre A, Hermabessiere P, et al.
Clin Gastroenterol Hepatol
. 2023 Aug;
22(8):1637-1645.e9.
PMID: 37573987
Background & Aims: Individual risk prediction of liver-related events (LRE) is needed for clinical assessment of nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) patients. We aimed to provide point-of-care validated...
8.
Mourino A, Rivera-Esteban J, Augustin S, Turu Santigosa E, Pericas J
Aten Primaria
. 2023 Apr;
55(6):102620.
PMID: 37043974
Objective: To investigate the prevalence of metabolic morbidity (MM) amongst prison inmates. Design: Multicentric, cross-sectional observational study. Setting: All (nine) prisons in Catalonia. Participants: Convicted inmates that are not in...
9.
Olveira A, Augustin S, Benlloch S, Ampuero J, Suarez-Perez J, Armesto S, et al.
Life (Basel)
. 2023 Feb;
13(2).
PMID: 36836776
Interleukin 17 (IL-17) is an effector cytokine that plays a key role in the pathogenesis of both psoriasis and metabolic-associated fatty liver disease (MAFLD), a condition that is more prevalent...
10.
Nicoara-Farcau O, Lozano J, Alonso C, Sidorova J, Villanueva C, Albillos A, et al.
Hepatology
. 2023 Feb;
77(6):2052-2062.
PMID: 36811400
Background And Aims: Patients with compensated cirrhosis with clinically significant portal hypertension (CSPH: HVPG > 10 mm Hg) have a high risk of decompensation. HVPG is, however, an invasive procedure...